News
Novo Nordisk, MAS and liver
Digest more
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
Pharmaceutical Technology on MSN1d
Wegovy becomes first GLP-1RA to gain FDA MASH approval
Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...
Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...
MedPage Today on MSN1d
Semaglutide Gets FDA Greenlight for MASH
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
The Emmy-nominated Tramell Tillman immediately blew his whistle, with the band striking up the Powerman 5000 song “Relax,” ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback